NASDAQ · Biotechnology

Gemini Therapeutics, Inc. (GMTX) Stock

$1.35 +0.00% NASDAQ: GMTX Healthcare

Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation.

Valuation

MetricValue
Price$1.35
Market Cap$25.49M
P/E Ratio-0.22
P/B Ratio0.03
P/S Ratio—
EPS (TTM)$-6.01
52-Week High$24.70
52-Week Low$1.35
Dividend Yield—

Financials & Margins

MetricValue
ROE-28.65%
ROA-26.27%
ROCE-30.65%
Gross Margin—
Operating Margin—
Net Margin—
Debt/Equity0.04
Current Ratio21.73

Annual Financials (USD)

Metric20212022202320242025
Revenue—————
Operating Profit$-31.0M$-47.0M$-91.0M$-130.0M$-236.0M
Net Profit$-36.0M$-47.0M$-76.0M$-109.0M$-212.0M
EPS$-40.95$-45.05$-3.42$-3.96$-6.01
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$92.0M$200.0M$368.0M$497.0M$807.0M
Total Liabilities$15.0M$24.0M$23.0M$53.0M$67.0M
Cash$88.0M$195.0M$360.0M$192.0M$91.0M
Borrowings$14.0M$14.0M—$28.0M$29.0M

Latest News

OP Pohjola's President and Group CEO Timo Ritakallio has announced that he will retire on 1 July 2027 as specified in his executive contract GlobeNewswire · Jul 23, 2026 Tocvan Discovers New High-Grade At-Surface Silver-Gold Zone 900 m East of Pilot Facility at Gran Pilar Project ACCESS Newswire · Jul 23, 2026 Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 Eco (Atlantic) Oil and Gas Ltd Announces Audited Results for the Year Ended 31 March 2026 ACCESS Newswire · Jul 23, 2026 OP Corporate Bank plc's Half-year Financial Report 1 January–30 June 2026 GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-28.0M$-42.0M$-73.0M$-94.0M$-180.0M
Investing Cash Flow$0$0$0$-292.0M$-394.0M
Financing Cash Flow$90.0M$149.0M$239.0M$218.0M$473.0M
Net Cash Flow$62.0M$107.0M$166.0M$-168.0M$-101.0M
Free Cash Flow$-28.0M$-42.0M$-74.0M$-94.0M$-181.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-710.03%
Quick Ratio21.73
Interest Coverage-118.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Gemini Therapeutics, Inc.

Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.

Gemini Therapeutics, Inc. is headquartered in US.

Gemini Therapeutics, Inc. (GMTX) stock trades at $1.35 with a market capitalization of $25.49M. The stock is valued at a price-to-earnings (P/E) ratio of -0.22, price-to-book of 0.03. Over the past 52 weeks the stock has ranged between $1.35 and $24.70, and currently trades 94.5% below its 52-week high.

On profitability, Gemini Therapeutics, Inc. generates a return on equity (ROE) of -28.65%, return on capital employed of -30.65%.

Official website: www.geminitherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides